Date: 2016-06-15
Type of information: Private placement
Company: Corbus Pharmaceuticals (USA - MA)
Investors:
Amount: $15 million
Funding type: private placement
Planned used: The net proceeds from the offering will be used towards the continued advancement of the Company's clinical development programs of its investigational drug, Resunab, for the treatment of cystic fibrosis , diffuse cutaneous systemic sclerosis , skin-predominant dermatomyositis and systemic lupus erythematosus.
Others: * On June 15, 2016, Corbus Pharmaceuticals announced sale of shares of its common stock in a registered direct offering to institutional and accredited investors, including Perceptive Advisors, LLC, Ghost Tree Capital, LLC, DAFNA Capital Management, LLC and other healthcare-oriented fundamental investors. The Company sold 5,960,000 shares of its common stock at a purchase price of $2.50 per share, with gross proceeds of $14.9 million and net proceeds after offering expenses of $14.8 million. The shares were offered by Corbus pursuant to a shelf registration statement on Form S-3 (File No. 333-207936) which was declared effective on November 19, 2015 by the Securities and Exchange Commission. * On June 10, 2016, Corbus Pharmaceuticals announced that the Company has entered into a Securities Purchase Agreement for the sale of shares of its common stock in a registered direct offering to investors, including several healthcare oriented fundamental institutional investors. The Company is selling 5,960,000 shares at a purchase price of $2.50 per share with gross proceeds to the Company totaling $14.9 million.
Therapeutic area: Fibrotic diseases - Inflammatory diseases
